<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05623410</url>
  </required_header>
  <id_info>
    <org_study_id>CBAP-PLN-002</org_study_id>
    <nct_id>NCT05623410</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines</brief_title>
  <official_title>A Randomized, Double-Blind, Active-Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of &quot;ATGC-110&quot; Compared to &quot;Xeomin®&quot; in Patients Who Need Moderate or Severe Glabellar Line Improvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ATGC Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ATGC Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison&#xD;
      with Xeomin for a total of 16 weeks after the administration in treatment of glabellar frown&#xD;
      lines.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 11, 2022</start_date>
  <completion_date type="Anticipated">June 10, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 10, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement rate (%) of glabellar lines at maximum frown according to the investigator's on-site evaluation at week 4 compared to the baseline</measure>
    <time_frame>4 weeks after the administration</time_frame>
    <description>Investigators will assess subjects' glabellar lines with Facial Wrinkle Scale (FWS) at maximal frown; 0=none, 1=mild, 2=moderate or 3=severe.&#xD;
Only the subjects whose FWS score is 0- or 1-grade when it's assessed and ≥ 2-grade improvement from baseline will be defined as their glabellar lines are improved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement rate (%) of glabellar lines at maximum frown according to the investigator's on-site evaluation at weeks 8, 12, and 16 compared to the baseline</measure>
    <time_frame>8, 12 and 16 weeks after the administration</time_frame>
    <description>Investigators will assess subjects' glabellar lines with Facial Wrinkle Scale (FWS) at maximal frown; 0=none, 1=mild, 2=moderate or 3=severe.&#xD;
Only the subjects whose FWS score is 0- or 1-grade when it's assessed and ≥ 2-grade improvement from baseline will be defined as their glabellar lines are improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate (%) of glabellar lines at rest according to the investigator's on-site evaluation at weeks 4, 8, 12, and 16 compared to the baseline</measure>
    <time_frame>4, 8, 12 and 16 weeks after the administration</time_frame>
    <description>Investigators will assess subjects' glabellar lines with Facial Wrinkle Scale (FWS) at rest; 0=none, 1=mild, 2=moderate or 3=severe.&#xD;
Only the subjects whose FWS score is 0- or 1-grade when it's assessed and ≥ 2-grade improvement from baseline will be defined as their glabellar lines are improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate (%) of glabellar lines at maximum frown evaluated through photographs by the independent evaluator at weeks 4, 8, 12, and 16 compared to the baseline</measure>
    <time_frame>4, 8, 12 and 16 weeks after the administration</time_frame>
    <description>Independent evaluator will assess subjects' glabellar lines with Facial Wrinkle Scale (FWS) at maximal frown; 0=none, 1=mild, 2=moderate or 3=severe.&#xD;
Only the subjects whose FWS score is 0- or 1-grade when it's assessed and ≥ 2-grade improvement from baseline will be defined as their glabellar lines are improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement rate (%) of glabellar lines at rest evaluated through photographs by the independent evaluator at weeks 4, 8, 12, and 16 compared to the baseline</measure>
    <time_frame>4, 8, 12 and 16 weeks after the administration</time_frame>
    <description>Independent evaluator will assess subjects' glabellar lines with Facial Wrinkle Scale (FWS) at rest; 0=none, 1=mild, 2=moderate or 3=severe.&#xD;
Only the subjects whose FWS score is 0- or 1-grade when it's assessed and ≥ 2-grade improvement from baseline will be defined as their glabellar lines are improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects whose FWS score is 0- or 1-grade at maximal frown according to the investigator's on-site evaluation at week 4, 8, 12, and 16</measure>
    <time_frame>4, 8, 12 and 16 weeks after the administration</time_frame>
    <description>Investigators will assess subjects' glabellar lines with Facial Wrinkle Scale (FWS) at maximal frown; 0=none, 1=mild, 2=moderate or 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects whose FWS score is 0- or 1-grade at rest according to the investigator's on-site evaluation at week 4, 8, 12, and 16</measure>
    <time_frame>4, 8, 12 and 16 weeks after the administration</time_frame>
    <description>Investigators will assess subjects' glabellar lines with Facial Wrinkle Scale (FWS) at rest; 0=none, 1=mild, 2=moderate or 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects whose FWS score is 0- or 1-grade at maximal frown evaluated through photographs by the independent evaluator at week 4, 8, 12, and 16</measure>
    <time_frame>4, 8, 12 and 16 weeks after the administration</time_frame>
    <description>Independent evaluator will assess subjects' glabellar lines with Facial Wrinkle Scale (FWS) at rest; 0=none, 1=mild, 2=moderate or 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects whose FWS score is 0- or 1-grade at rest evaluated through photographs by the independent evaluator at week 4, 8, 12, and 16</measure>
    <time_frame>4, 8, 12 and 16 weeks after the administration</time_frame>
    <description>Independent evaluator will assess subjects' glabellar lines with Facial Wrinkle Scale (FWS) at rest; 0=none, 1=mild, 2=moderate or 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects whose FWS score is improved ≥ 2 grade improvement according to the subject's evaluation at week 4, 8, 12, and 16</measure>
    <time_frame>4, 8, 12 and 16 weeks after the administration</time_frame>
    <description>Subjects will assess their glabellar lines with Facial Wrinkle Scale (FWS) at rest; 0=none, 1=mild, 2=moderate or 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of subjects' satisfaction at weeks 4, 8, 12, and 16</measure>
    <time_frame>4, 8, 12 and 16 weeks after the administration</time_frame>
    <description>If the subject's satisfaction evaluation score is 6 points or higher, it is evaluated as satisfactory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects whose FWS score is imporved ≥ 2 grade improvement at maximal frown according to the investigator's on-site and subject's evaluation at weeks 4, 8, 12, and 16</measure>
    <time_frame>4, 8, 12 and 16 weeks after the administration</time_frame>
    <description>If the glabellar line score evaluated by the subject is +2 points or higher, it is evaluated as improved</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A(ATGC-110)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATGC-110 will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Incobotulinumtoxin A (Xeomin®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Xeomin® will be injected to 5 glabellar lines (Each 4U/0.1ml, Total 20U/0.5ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ATGC-110</intervention_name>
    <description>ATGC-110 is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.</description>
    <arm_group_label>Botulinum toxin type A(ATGC-110)</arm_group_label>
    <other_name>Clostridium Botulinum Type A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Xeomin®</intervention_name>
    <description>Xeomin® is a prescription medicine that is injected into muscles and used to improve the moderate to severe glabellar lines. It should be reconstituted with sterile, preservative-free 0.9% saline before use.</description>
    <arm_group_label>Incobotulinumtoxin A (Xeomin®)</arm_group_label>
    <other_name>Incobotulinumtoxin A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects aged between 19 to 65 years&#xD;
&#xD;
          -  Subjects assigned a glabellar line severity grade of 2 or greater (moderate) at&#xD;
             maximum frown assessed by the Investigator&#xD;
&#xD;
          -  Subjects who provide written consent to voluntarily participate in the study after&#xD;
             receiving and understanding a detailed explanation of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with diseases that may affect neuromuscular function, such as Myasthenia&#xD;
             gravis, Lambert-Eaton syndrome, Amyotrophic lateral sclerosis, or motor neuropathy&#xD;
             etc.)&#xD;
&#xD;
          -  Subjects with the history of eyelid paralysis or ptosis&#xD;
&#xD;
          -  Subjects with significant facial asymmetry&#xD;
&#xD;
          -  Subjects whose glabellar lines cannot be satisfactorily improved with physical methods&#xD;
             since lines are not flattened even using hands&#xD;
&#xD;
          -  Infection, dermatological condition or scar at the treatment injection sites&#xD;
&#xD;
          -  Subjects currently suffering acute diseases&#xD;
&#xD;
          -  Subjects with the history of excessive alcohol consumption or drug addiction&#xD;
&#xD;
          -  Condition including anxiety disorder, or any other significant psychiatric disorder&#xD;
             (e.g. depression), in the investigator's opinion&#xD;
&#xD;
          -  Subjects with concomitant illnesses that make them unsuitable for participation in the&#xD;
             study by the Investigator such as malignant tumors, immunodeficiency (immune&#xD;
             deficiency), kidney disease, liver disease, or lung disease&#xD;
&#xD;
          -  Subjects with the history of treatment of the glabellar region (including the&#xD;
             forehead) such as face lifting, permanent implants, or fillers&#xD;
&#xD;
          -  Subjects who have received other procedures that may affect the assessment of the&#xD;
             glabellar or forehead lines during the following periods; Within 6 months of&#xD;
             screening: main ingredient hyaluronic acid skin filler, dermal resurfacing,&#xD;
             chemical/mechanical skin peeling, skin peeling, Dermal photorejuvenation; Within 12&#xD;
             months of screening: Dermal fillers other than the main ingredient hyaluronic acid,&#xD;
             nonpermanent soft tissue fillers&#xD;
&#xD;
          -  Subjects who have received medication that inhibits neuromuscular function within the&#xD;
             4 weeks prior to screening such as muscle relaxants, anticholinergics, benzodiazepines&#xD;
             and similar drugs, benzamides, tetracycline antibiotics, lincomycin antibiotics, and&#xD;
             aminoglycoside antibiotics&#xD;
&#xD;
          -  Subjects who have taken retinoid drugs (Isotretinoin, Alitretinoin, etc.) during the&#xD;
             following period; Oral and systemic use: within 6 months of screening Topical applied&#xD;
             on the face: within 3 months of screening&#xD;
&#xD;
          -  Subjects who have received aspirin or NSAIDs within 7 days prior to administration of&#xD;
             the IP (Use of low-dose aspirin (325 mg/day or less) to prevent blood clotting is&#xD;
             allowed).&#xD;
&#xD;
          -  Subjects taking anticoagulants or antiplatelet agents (Use of low-dose aspirin (325&#xD;
             mg/day or less) to prevent blood clotting is allowed)&#xD;
&#xD;
          -  Subjects who are allergic or sensitive to the IP or its components&#xD;
&#xD;
          -  Subjects who have received botulinum toxin preparations within 6 months from the time&#xD;
             of screening&#xD;
&#xD;
          -  Female subjects of childbearing age who do not agree to practice contraception using&#xD;
             medically allowed contraceptive methods during the study period (hormonal&#xD;
             contraception, IUD (intrauterine device) or IUS (intrauterine system), tubal ligation,&#xD;
             dual protection (using a combination of male condom, female condom, cervical cap,&#xD;
             contraceptive diaphragm, or contraceptive sponge)&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Subjects planning a facial cosmetic procedure (skin fillers, photorejuvenation,&#xD;
             chemical/mechanical peeling, etc.) during the study period&#xD;
&#xD;
          -  Subjects who have participated in other clinical trials within 30 days prior to&#xD;
             participating in this study and have received an IP or medical device during the&#xD;
             previous clinical studies&#xD;
&#xD;
          -  Subjects directly related to the investigator (e.g. a dermatologist or plastic&#xD;
             surgeon)&#xD;
&#xD;
          -  Individuals who are not eligible for this study for any reason as per the&#xD;
             Investigator's discretion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nowon Eulji Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>November 13, 2022</study_first_submitted>
  <study_first_submitted_qc>November 13, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2022</study_first_posted>
  <last_update_submitted>February 2, 2023</last_update_submitted>
  <last_update_submitted_qc>February 2, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

